• Je něco špatně v tomto záznamu ?

In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa

L. Malisova, I. Vrbova, K. Pomorska, V. Jakubu, H. Zemlickova

. 2023 ; 29 (10) : 485-491. [pub] 20230822

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001154

The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order Enterobacterales, and 40 strains of Pseudomonas aeruginosa. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, blaIMP, blaGES) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (n = 149) strains of the order Enterobacterales and 77.5% (n = 31) of P. aeruginosa isolates were inhibited at minimal inhibitory concentration (MIC) ≤2 mg/L. Values MIC50/MIC90 were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for P. aeruginosa. One isolate (Klebsiella pneumoniae) harboring two carbapenemases (blaOXA-48, blaNDM) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, blaNDM carbapenemase prevailed (43.3%, n = 29), followed by blaOXA-48 (31.3%, n = 21) and blaKPC (4.5%, n = 3). blaIMP (n = 8) and blaVIM (n = 1) metallo-β-lactamases dominated in cefiderocol-resistant P. aeruginosa (n = 9) isolates. Very good susceptibility (100%) to this drug showed blaGES-positive strains of P. aeruginosa (n = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (n = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001154
003      
CZ-PrNML
005      
20241231101948.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/mdr.2023.0090 $2 doi
035    __
$a (PubMed)37610876
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Malisova, Lucia $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $u Department of Microbiology, 3rd Faculty of Medicine, Kralovske Vinohrady University Hospital and National Institute of Public Health, Charles University, Prague, Czech Republic
245    10
$a In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa / $c L. Malisova, I. Vrbova, K. Pomorska, V. Jakubu, H. Zemlickova
520    9_
$a The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order Enterobacterales, and 40 strains of Pseudomonas aeruginosa. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, blaIMP, blaGES) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (n = 149) strains of the order Enterobacterales and 77.5% (n = 31) of P. aeruginosa isolates were inhibited at minimal inhibitory concentration (MIC) ≤2 mg/L. Values MIC50/MIC90 were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for P. aeruginosa. One isolate (Klebsiella pneumoniae) harboring two carbapenemases (blaOXA-48, blaNDM) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, blaNDM carbapenemase prevailed (43.3%, n = 29), followed by blaOXA-48 (31.3%, n = 21) and blaKPC (4.5%, n = 3). blaIMP (n = 8) and blaVIM (n = 1) metallo-β-lactamases dominated in cefiderocol-resistant P. aeruginosa (n = 9) isolates. Very good susceptibility (100%) to this drug showed blaGES-positive strains of P. aeruginosa (n = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (n = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.
650    12
$a karbapenemy $x farmakologie $7 D015780
650    12
$a antibakteriální látky $x farmakologie $7 D000900
650    _2
$a Pseudomonas aeruginosa $7 D011550
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a beta-laktamasy $x genetika $x metabolismus $7 D001618
650    _2
$a Enterobacteriaceae $x genetika $x metabolismus $7 D004755
650    _7
$a cefiderokol $7 D000097602 $2 czmesh
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vrbová, Iveta $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $7 xx0327427
700    1_
$a Pomorska, Katarina $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Jakubu, Vladislav $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $u Department of Microbiology, 3rd Faculty of Medicine, Kralovske Vinohrady University Hospital and National Institute of Public Health, Charles University, Prague, Czech Republic
700    1_
$a Zemlickova, Helena $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $u Department of Microbiology, 3rd Faculty of Medicine, Kralovske Vinohrady University Hospital and National Institute of Public Health, Charles University, Prague, Czech Republic
773    0_
$w MED00008749 $t Microbial drug resistance $x 1931-8448 $g Roč. 29, č. 10 (2023), s. 485-491
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37610876 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20241231101947 $b ABA008
999    __
$a ok $b bmc $g 2049637 $s 1210848
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 29 $c 10 $d 485-491 $e 20230822 $i 1931-8448 $m Microbial drug resistance $n Microb Drug Resist $x MED00008749
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...